vs
ASBURY AUTOMOTIVE GROUP INC（ABG）与渤健（BIIB）财务数据对比。点击上方公司名可切换其他公司
ASBURY AUTOMOTIVE GROUP INC的季度营收约是渤健的1.8倍（$4.1B vs $2.3B），ASBURY AUTOMOTIVE GROUP INC净利率更高（4.6% vs -2.1%，领先6.7%），ASBURY AUTOMOTIVE GROUP INC同比增速更快（-0.9% vs -7.1%），过去两年渤健的营收复合增速更高（-0.2% vs -1.6%）
阿斯伯里汽车集团是一家总部位于亚特兰大地区的美国企业，1995年成立，业务覆盖美国多地的汽车经销领域，在2025年《财富》世界500强榜单中位列第242位，是美国汽车经销行业颇具规模的代表性企业。
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
ABG vs BIIB — 直观对比
营收规模更大
ABG
是对方的1.8倍
$2.3B
营收增速更快
ABG
高出6.3%
-7.1%
净利率更高
ABG
高出6.7%
-2.1%
两年增速更快
BIIB
近两年复合增速
-1.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $4.1B | $2.3B |
| 净利润 | $187.8M | $-48.9M |
| 毛利率 | 17.7% | 78.3% |
| 营业利润率 | 4.7% | -2.5% |
| 净利率 | 4.6% | -2.1% |
| 营收同比 | -0.9% | -7.1% |
| 净利润同比 | 42.2% | -118.3% |
| 每股收益（稀释后） | $9.87 | $-0.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABGBIIB
| Q1 26 | $4.1B | — | ||
| Q4 25 | $4.7B | $2.3B | ||
| Q3 25 | $4.8B | $2.5B | ||
| Q2 25 | $4.4B | $2.6B | ||
| Q1 25 | $4.1B | $2.4B | ||
| Q4 24 | $4.5B | $2.5B | ||
| Q3 24 | $4.2B | $2.5B | ||
| Q2 24 | $4.2B | $2.5B |
净利润ABGBIIB
| Q1 26 | $187.8M | — | ||
| Q4 25 | $60.0M | $-48.9M | ||
| Q3 25 | $147.1M | $466.5M | ||
| Q2 25 | $152.8M | $634.8M | ||
| Q1 25 | $132.1M | $240.5M | ||
| Q4 24 | $128.8M | $266.7M | ||
| Q3 24 | $126.3M | $388.5M | ||
| Q2 24 | $28.1M | $583.6M |
毛利率ABGBIIB
| Q1 26 | 17.7% | — | ||
| Q4 25 | 17.0% | 78.3% | ||
| Q3 25 | 16.7% | 73.4% | ||
| Q2 25 | 17.2% | 77.1% | ||
| Q1 25 | 17.5% | 74.1% | ||
| Q4 24 | 16.6% | 76.2% | ||
| Q3 24 | 16.9% | 74.1% | ||
| Q2 24 | 17.2% | 77.8% |
营业利润率ABGBIIB
| Q1 26 | 4.7% | — | ||
| Q4 25 | 2.7% | -2.5% | ||
| Q3 25 | 5.1% | 22.0% | ||
| Q2 25 | 5.9% | 28.1% | ||
| Q1 25 | 5.6% | 12.8% | ||
| Q4 24 | 5.3% | 11.9% | ||
| Q3 24 | 5.5% | 18.3% | ||
| Q2 24 | 2.4% | 28.3% |
净利率ABGBIIB
| Q1 26 | 4.6% | — | ||
| Q4 25 | 1.3% | -2.1% | ||
| Q3 25 | 3.1% | 18.4% | ||
| Q2 25 | 3.5% | 24.0% | ||
| Q1 25 | 3.2% | 9.9% | ||
| Q4 24 | 2.9% | 10.9% | ||
| Q3 24 | 3.0% | 15.8% | ||
| Q2 24 | 0.7% | 23.7% |
每股收益（稀释后）ABGBIIB
| Q1 26 | $9.87 | — | ||
| Q4 25 | $3.14 | $-0.35 | ||
| Q3 25 | $7.52 | $3.17 | ||
| Q2 25 | $7.76 | $4.33 | ||
| Q1 25 | $6.71 | $1.64 | ||
| Q4 24 | $6.53 | $1.82 | ||
| Q3 24 | $6.37 | $2.66 | ||
| Q2 24 | $1.39 | $4.00 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $25.3M | — |
| 总债务越低越好 | — | $6.3B |
| 股东权益账面价值 | $3.9B | $18.3B |
| 总资产 | — | $29.4B |
| 负债/权益比越低杠杆越低 | — | 0.34× |
8季度趋势，按日历期对齐
现金及短期投资ABGBIIB
| Q1 26 | $25.3M | — | ||
| Q4 25 | $500.0K | — | ||
| Q3 25 | $900.0K | — | ||
| Q2 25 | $2.8M | — | ||
| Q1 25 | $6.6M | — | ||
| Q4 24 | $14.4M | — | ||
| Q3 24 | $9.0M | — | ||
| Q2 24 | $10.5M | — |
总债务ABGBIIB
| Q1 26 | — | — | ||
| Q4 25 | $3.1B | $6.3B | ||
| Q3 25 | $3.5B | $6.3B | ||
| Q2 25 | $3.0B | $6.3B | ||
| Q1 25 | $3.0B | $4.5B | ||
| Q4 24 | $3.0B | $6.3B | ||
| Q3 24 | $3.3B | $4.5B | ||
| Q2 24 | $3.5B | $6.3B |
股东权益ABGBIIB
| Q1 26 | $3.9B | — | ||
| Q4 25 | $3.9B | $18.3B | ||
| Q3 25 | $3.9B | $18.2B | ||
| Q2 25 | $3.8B | $17.6B | ||
| Q1 25 | $3.6B | $17.0B | ||
| Q4 24 | $3.5B | $16.7B | ||
| Q3 24 | $3.4B | $16.4B | ||
| Q2 24 | $3.3B | $15.9B |
总资产ABGBIIB
| Q1 26 | — | — | ||
| Q4 25 | $11.6B | $29.4B | ||
| Q3 25 | $11.8B | $29.2B | ||
| Q2 25 | $10.1B | $28.3B | ||
| Q1 25 | $10.2B | $28.0B | ||
| Q4 24 | $10.3B | $28.0B | ||
| Q3 24 | $10.2B | $28.3B | ||
| Q2 24 | $10.3B | $26.8B |
负债/权益比ABGBIIB
| Q1 26 | — | — | ||
| Q4 25 | 0.79× | 0.34× | ||
| Q3 25 | 0.90× | 0.35× | ||
| Q2 25 | 0.78× | 0.36× | ||
| Q1 25 | 0.83× | 0.27× | ||
| Q4 24 | 0.86× | 0.38× | ||
| Q3 24 | 0.98× | 0.28× | ||
| Q2 24 | 1.05× | 0.40× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $511.9M |
| 自由现金流经营现金流 - 资本支出 | — | $468.0M |
| 自由现金流率自由现金流/营收 | — | 20.5% |
| 资本支出强度资本支出/营收 | — | 1.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $2.1B |
8季度趋势，按日历期对齐
经营现金流ABGBIIB
| Q1 26 | — | — | ||
| Q4 25 | $151.9M | $511.9M | ||
| Q3 25 | $306.9M | $1.3B | ||
| Q2 25 | $91.4M | $160.9M | ||
| Q1 25 | $225.0M | $259.3M | ||
| Q4 24 | $244.2M | $760.9M | ||
| Q3 24 | $404.3M | $935.6M | ||
| Q2 24 | $-154.4M | $625.8M |
自由现金流ABGBIIB
| Q1 26 | — | — | ||
| Q4 25 | — | $468.0M | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $134.3M | ||
| Q1 25 | — | $222.2M | ||
| Q4 24 | — | $721.6M | ||
| Q3 24 | — | $900.6M | ||
| Q2 24 | — | $592.3M |
自由现金流率ABGBIIB
| Q1 26 | — | — | ||
| Q4 25 | — | 20.5% | ||
| Q3 25 | — | 48.4% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | 9.1% | ||
| Q4 24 | — | 29.4% | ||
| Q3 24 | — | 36.5% | ||
| Q2 24 | — | 24.0% |
资本支出强度ABGBIIB
| Q1 26 | — | — | ||
| Q4 25 | — | 1.9% | ||
| Q3 25 | — | 1.8% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 1.6% | ||
| Q3 24 | — | 1.4% | ||
| Q2 24 | — | 1.4% |
现金转化率ABGBIIB
| Q1 26 | — | — | ||
| Q4 25 | 2.53× | — | ||
| Q3 25 | 2.09× | 2.73× | ||
| Q2 25 | 0.60× | 0.25× | ||
| Q1 25 | 1.70× | 1.08× | ||
| Q4 24 | 1.90× | 2.85× | ||
| Q3 24 | 3.20× | 2.41× | ||
| Q2 24 | -5.49× | 1.07× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABG
| New vehicle | $2.1B | 51% |
| Retail | $1.1B | 26% |
| Parts and service | $626.8M | 15% |
| Finance and insurance, net | $179.0M | 4% |
| Wholesale | $146.8M | 4% |
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
